2,4-SUBSTITUTED QUINAZOLINE AS JAK2 INHIBITOR: DOCKING AND MOLECULAR DYNAMICS STUDY by BUGGANA, SIVA JYOTHI et al.
 
Original Article 
2,4-SUBSTITUTED QUINAZOLINE AS JAK2 INHIBITOR: DOCKING AND MOLECULAR 
DYNAMICS STUDY 
 
SIVA JYOTHI BUGGANA1, MANI CHANDRIKA PATURI1, RAJENDRA PRASAD VVS2* 
1Department of Pharmaceutical Chemistry, Bojjam Narasimhulu Pharmacy College for Women, Hyderabad, India, 2Centre for Molecular 
Cancer Research (CMCR), Vishnu Institute of Pharmaceutical and Educational Research, Narsapur, India 
Email: rajendraprasad.vvs@viper.ac.in 
Received: 07 Nov 2019, Revised and Accepted: 17 Dec 2019 
ABSTRACT 
Objective: The involvement of Janus kinase2/signal transducer and activator of transcription (JAK2/STAT3) pathway reported in various solid 
tumors made authors study the conformational changes of JAK2-3e complex which was previously reported with a moderate percentage of In-vitro 
JAK2 inhibition.  
Methods: In this present study Compound 3e was reported with a moderate percentage of inhibition of JAK2 protein selected for performing 
molecular docking and molecular dynamics studies to elucidate the conformational changes with JAK2-3e complex. Docking studies were performed 
using ChemSketch to draw the structure of the compound and optimized/energy minimized using the Ligprep module of Schrodinger suite, 
employing optimized potentials for liquid simulations (OPLS-2005) force field. Molecular dynamics simulations were performed for 10 ns for 
complex using TIP4PEW water solvent model and neutralized by adding sodium ions. 
Results: Docking studies of Compound 3e which has been reported as one of the effective cytotoxic agents and a moderate percentage of In-vitro 
JAK2 inhibition among the series, showed H-bond interaction with leucine 855, serine936, aspartine994. Dock score and Ligand binding energy 
with protein suggested compound 3e has shown-4.049,-66.003 kcal/mol respectively. Molecular dynamics simulations elucidated the mechanistic 
insight of JAK-2 inhibition. The Root means square deviation (RMSD) pattern of both protein and ligands in the JAK2-3e complex observed to be 
different over 10 ns simulation. In the JAK2-3e complex, an exponential increase in RMSD of Cα and side-chain amino acids is observed during the 
first 1-3 ns simulation and is stabilized till 10 ns. During the 10 ns simulation, ligand 3e seems to be stable in the complex with an overall 
deviation<1 Å, despite a drastic increase between 1-3 ns. The ligand RMSD plot suggests that the ligand 3e remained intact within the binding site of 
the protein and longer time period simulation may elucidate the binding pattern and fate of ligand 3e. 
Conclusion: Results from molecular dynamics simulations elucidated the mechanistic insight of JAK-2 inhibition by 2, 4 disubstituted quinazoline 
compound that is N’(2-(4-nitrophenyl)quinazoline-4-yl) isonicotinohydrazide) and their binding phenomenon. Molecular docking studies further 
supported the elucidation of binding patterns of the molecules in the JAK-2 protein environment. Further simulations with a longer time period may 
provide deeper insights into ligand interactions in the protein environment. It is noteworthy to use compound 3e as a new scaffold for further 
development of multifunctional compounds. 
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INTRODUCTION 
Cancer is one of the major threats to human life worldwide and is 
the second leading cause of death in the United States. An estimated 
6, 06,880 Americans will die from cancer in 2019 [1], corresponding 
to almost 1700 deaths per day. The greatest number of deaths is 
from cancers of the lung, prostate, and colorectum in men and the 
lung, breast, and colorectum in women. Even cancer is the second 
most common cause of death among children aged 1-14 y in the 
United States. In 2019, an estimated 11,060 children will be 
diagnosed with cancer and 1,190 will die from the disease. 
The sequence of events like cell cycle progression, cell division, and 
proliferation can be controlled by a cascade of enzymes such as 
protein kinases [2]. These enzymes are responsible for regulating 
physiological mechanisms, including cell differentiation, migration, 
and metabolism. These enzymes are divided into three categories 
like tyrosine kinases [3], serine/threonine kinases [4], and Histidine 
kinases [5]. When the protein kinases are expressed in mutated, 
unregulated forms (or) produced abnormally in high levels these 
can transform normal cells into carcinogenic phenotypes [6, 7]. JAK-
STAT pathway transduces extracellular signals into transcriptional 
programs which can regulate cell growth and differentiation [8, 9]. 
The mammary gland and ovary where the JAK-STAT pathway is 
extensively investigated. During puberty, pregnancy the mammary 
cells and ovary cells exposed to signaling pathways that inhibit 
apoptosis, induce proliferation and invoke differentiation. The 
signaling pathways are responsible for bringing out these changes in 
breast and ovarian cells. The distinct functions of STAT3 and STAT5 
have received attention in the context of breast cancer and ovarian 
cancer. STAT3 activity can be modulated through STAT5 activity and 
their combined functions can have an impact on the progression of 
breast and ovarian cancers [10]. The cell division and angiogenesis 
required for tumor growth and metastasis are controlled by protein 
kinases. Hence there is a necessity to develop non-toxic and selective 
inhibitors of protein kinases in tumor cells represent the exciting 
targets for cancer treatment. 
The heterocycles are widely known as bioactive molecules and are 
considered as an important synthetic target for the development of 
novel therapeutic agents [11-12]. Quinazoline is one of the 
heterocycles used as a basic framework that produces biologically 
active compounds and drug molecules [13]. Due to wide range of 
biological activities like antimicrobial [14, 15], antimalarial [16], 
anti-inflammatory [17-19] anti-convulsant [20, 21], 
antihypertensive [22], anti-oxidant [23], anti-viral [24], anti-HIV 
[25] and anti-cancer [26-29] quinazoline and its derivatives 
attracted the attention of both biologists and chemists. Quinazoline 
and its derivatives have been identified as a new class of cancer 
chemotherapeutic agents [30] with significant therapeutic efficacy 
against solid tumors [31-43]. 
International Journal of Pharmacy and Pharmaceutical Sciences 
Print ISSN: 2656-0097 | Online ISSN: 0975-1491                          Vol 12, Issue 2, 2020 
Rajendra et al. 
Int J Pharm Pharm Sci, Vol 12, Issue 2, 48-54 
49 
In our previous work [44] we have evaluated them for their invitro 
JAK 2 inhibition which we have previously proved their cytotoxic 
potentials against human breast (MDA-MB-231) and ovarian cancer 
(SK-O-V3) cell lines. The synthesis of these compounds is shown in 
scheme [1]. In the present work, the continuation of our previous 
work in order to elucidate the mechanistic insights of the 2, 4-
disubstituted quinazoline molecules, we have performed docking 
studies of compound 3e against JAK-2 protein. Additionally, 
molecular dynamics simulations of compound 3e conducted to 
elucidate the conformational changes of the JAK-2-Quinazoline 
complex. 
MATERIALS AND METHODS 
Molecular docking and binding energy calculations 
The synthesized quinazoline derivative structure 3e was drawn 
using ChemSketch and optimized/energy minimized using the 
Ligprep module of Schrodinger suite, employing OPLS-2005 
(optimized potentials for liquid simulations) force field. A 3D digital 
structure of the target kinase domain of JAK2 protein was retrieved 
from the Protein databank website (PDB Id: 3RVG). The protein 
structure was optimized using the Protein Preparation Wizard, by 
adding hydrogen atoms to satisfy the valences and optimized by 
using the OPLS-2005 force field. Protein-ligand interactions and 
conformational changes were examined by using the Glide XP 
docking protocol [45]. Glide XP modules include two steps, Receptor 
Grid generation and ligand docking. A grid was generated 
considering the volume of the active binding pocket of the protein 
and all ligands were docked into the active site of the target protein. 
Glide score includes a steric clash term, adds polar terms featured by 
Schrodinger to correct electrostatic mismatches. Glide score is a 
combination of hydrophilic, hydrophobic, metal-binding groups, Van 
der Waals energy, freezing rotatable bonds, and polar interactions 
with receptors. MM/GBSA calculations were performed for the 
docked protein-ligand complexes to determine the binding energy. 
The total free energy of binding is then expressed in the form below 
mentioned equation:  
ΔGbind = Gcomplex-(Gprotein+Gligand)  
where ΔGbind is ligand binding energy. 
In other terms, 
ΔGbind = ΔEgas+ΔGsolvation-TΔS 
Where gas phase molecular mechanical energy is ΔEgas, solvation 
free energy are ΔGsolvation (polar and non-polar contributions) and 
TΔS is the entropy [46]. 
 
 
Fig. 1: Compound 3e
 
 
Scheme 1: Synthesis of 2,4-disubstituted quinazolines 
 
Molecular dynamics 
The docked complex of the JAK2 protein and compound 3e was selected 
for molecular dynamics studies using Desmond by D. E. Shaw Research 
as discussed in our previous publication [44]. Molecular dynamics 
simulations were performed for 10 ns for complex using the TIP4PEW 
water solvent model and neutralized by adding sodium ions. The system 
was maintained at 0.15 M salt concentration (Na+Cl-) simulating the 
physiological conditions and dynamics simulations were performed 
using OPLS 2005 force field and NPT ensemble (constant number of 
atoms, at constant pressure [1.01352 bar], and constant temperature 
[300K] for 10 ns. For system ensemble, Nose-Hoover chain thermostat 
with a relaxation time of 1 ps and Martyna-Tobias-Klein barostat with 2 
ps relaxation time and isocratic cooling style and Coulombic interactions 
were Cut off at 9Å radius were used. 
RESULTS AND DISCUSSION 
Molecular docking and binding energy calculations 
Considering the association of JAK2 in human solid tumors like breast 
and ovarian cancers, Molecular docking studies were performed to 
determine the protein-ligand interactions and also to understand the 
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conformational changes in the protein-ligand complex. Docking 
studies were performed with the compound which was evaluated for 
in vitro JAK-2 inhibition. Dock score of the tested compound-4.049 
(3e). Compound 3e which has been reported as one of the effective 
cytotoxic agents among the series showed H-bond interaction with 
leucine 855, serine936, aspartine994 (fig. 2 and 3). Ligand binding 
energy with protein suggested compound 3e has shown binding 
energy of-66.003 kcal/mol. 
  
 
Fig. 2: Protein-ligand interactions of compound 3e with JAK2 protein 
 
 
Fig. 3: Protein-ligand interactions of compound 3e with JAK2 protein 
 
Molecular dynamics 
Molecular dynamics simulations performed in the solvent 
environment at constant temperature and pressure have revealed 
the conformation changes of the JAK-2-3ecomplex. The stability of 
the complex is determined in terms of the RMSD and RMSF fig. 4 of 
the protein components along with the ligand. When compared to 
the loop region, alpha helices and beta strands are more rigid and 
thus fluctuations are relatively lower. Overall, the fluctuations in the 
loop region are observed to be higher in the JAK2-3e complex (up to 
5.4 Å). The RMSD pattern of both protein and ligands in the JAK2-3e 
complex observed to be different over 10 ns simulation (fig. 5). In 
the JAK2-3e complex, an exponential increase in RMSD of Cα and 
side-chain amino acids is observed during the first 1-3 ns simulation 
and is stabilized till 10 ns. During the 10 ns simulation, ligand 3e 
seems to be stable in the complex with an overall deviation<1 Å, 
despite a drastic increase between 1-3 ns. The ligand RMSD plot 
suggests that the ligand 3e remained intact within the binding site of 
the protein and longer time period simulation may elucidate the 
binding pattern and fate of ligand 3e. 
The ligand-protein contacts between compound 3e and JAK2 during 
the 10 ns simulation time frame are shown in fig. 6. During the 
simulation time frame, ASP 939 (46%), TYR 931 (71%), and LEU 
932 (94%) are the most interacted amino acids with compound 3e. 
In compound 3e, a prominent intra-molecular H-bond is observed 
between the Nitrogen atom of quinazoline moiety and a hydroxyl 
group. The fate of protein-ligand interactions and change in the total 
number of contacts over 10 ns is shown in fig. 7. 
In JAK2-3e complex, hydrophilic interactions are predominant in the 
binding affinity. In JAK2-3e complex, 9 water bridges are observed 
with GLN 853, LEU932, LYS857, TYR 931, LEU 932, ARG 980, GLY 
935, ARG 938 and SER 936 residues. Even ionic interactions also 
predominant in the binding affinity, two ionic linkages are observed 
at ARG938, Asp939. The overall interaction diagram of the JAK2-3e 
complex during molecular dynamic simulations is shown in fig. 8. 
The ligand torsion profiles of JAK2-3e seem to be different. The 
radial plots shown in fig. 9 explains the conformation of the ligand 
torsion throughout the course of the simulation (beginning of the 
simulation is in the center and the time evolution is radially 
outward). In JAK2-3d complex, torsion for the rotatable bonds 
between pyridine nucleus and carbonyl group, and hydrazide 
linkage, benzene ring, and nitro group diverge and this could have 
led to the extended conformational changes of the complex during 1-
3 ns simulation.  
The fate of the molecular properties (ligand RMSD, the radius of 
gyration [rGyr], intramolecular h-bonds, molecular surface area 
[MolSA], solvent accessible surface area [SASA], and polar surface 
area [PSA]) of compound 3e determined over 10 ns and shown in fig. 
10. Overall, during 10 ns no large changes were observed in 
compound 3e ligand properties. 
Rajendra et al. 
Int J Pharm Pharm Sci, Vol 12, Issue 2, 48-54 
51 
 
Fig. 4: Root mean square fluctuations (RMSF) for the C-alphas and side-chain residues of JAK2 protein in complex with compound 3e 
 
 
Fig. 5: Root mean square deviation (RMSD) of simulated complex 
 
 
Fig. 6: ligand-protein interaction probabilities in JAK2-3e complex during 10 ns time period 
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Fig. 7: Protein-ligand interaction diagram for10 ns time period 
 
 




Fig. 9: Ligand torsion profiles of JAK2-3e complex over 10 ns 
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Fig. 10: Fluctuations in the ligand properties over10 ns simulation 
 
DISCUSSION 
We have designed a convenient Insilico method for one of the novel 2, 
4 disubstituted quinazoline derivative that is N’(2-(4-
nitrophenyl)quinazoline-4-yl) isonicotinohydrazide) which was 
previously proved for their cytotoxic potentials. Enzyme inhibitory 
studies suggested that the inhibitory activity of this compound against 
JAK-2 protein could be the reason for the higher cytotoxicity. When we 
compare the molecular dynamics study of the compound 3e with our 
earlier work[44] in the same scheme that is for compound 3b(N1-(2-
(2,4-dihydroxy phenyl) quinazolin-4-yl) isonicotinohydrazide) and 
compound 3d(N1-(2(2-phenyl)quinazoline-4-yl)isonicotinohydrazide) 
for 20ns, it was observed that the compound with dihidroxy 
substitution shown fluctuation at 5-10ns whereas the compound 
without substitution shown the fluctuations after 15ns only. The 
compound 3e shown fluctuations during the first 1-3ns only. This may 
be because of the presence of nitro substitution at the para position. In 
docking studies, Compound 3e showed H-bond interaction with 
leucine 855, serine936, aspartine994, whereas the compounds 3b, 3d 
showed H-bond interaction with leucine 932, Arginine 938. More 
hydrogen bond interactions are observed due to nitro substitution at 
the para position. Hence In this present study Compound 3e from 2,4-
disubstituted quinazoline was reported with a moderate percentage of 
inhibition of JAK2 protein selected for performing molecular docking 
and molecular dynamics studies to elucidate the conformational 
changes and deeper insights with JAK2-3e complex. From the results, 
it is noteworthy that the compound 3e can be used as a new scaffold 
for designing novel cytotoxic agents with fewer toxic effects. 
CONCLUSION 
In the current investigation, one of novel 2, 4 disubstituted 
quinazoline derivatives that are N’(2-(4-nitrophenyl)quinazoline-4-
yl) isonicotinohydrazide) taken which was previously proved for 
their cytotoxic potentials. Enzyme inhibitory studies suggested that 
the inhibitory activity of these compounds against JAK-2 protein 
could be the reason for the higher cytotoxicity. Molecular docking 
studies further supported the elucidation of binding patterns of the 
molecules in the JAK-2 protein environment. Results from molecular 
dynamics simulations elucidated the mechanistic insight of JAK-2 
inhibition by 2, 4 disubstituted quinazoline compound that is N’(2-
(4-nitrophenyl)quinazoline-4-yl) isonicotinohydrazide) and their 
binding phenomenon. Even though simulations are conducted for a 
shorter duration of the period that is 10ns gave comparable results 
with our previous publication. Further simulations with a longer 
time period may provide deeper insights into ligand interactions in 
the protein environment. It is noteworthy to use compound 3e as a 
new scaffold for further development of multifunctional compounds.  
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